ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

roxadustat

Also written as “Roxadustat”, “FG-4592” and “ASP1517”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.

Drug pageRoxadustat: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 201347 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only221 open or runningphase 3since Jun 25, 2013Sep 15, 2009Oct 30, 2027phase 3 · NCT05970172
Kyntra Bio221 open or runningphase 4since Aug 8, 2019Sep 25, 2008Sep 2030phase 3 · NCT07722988
AstraZenecaits history only30 open or runningphase 4since Dec 3, 2020Jun 24, 2014none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kyntra Bio only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Sep 25, 2008.

  1. Jun 8, 2012Phase 2 study in Renal Insufficiency, ChronicNCT01630889 · 15 enrolled · United States, Puerto Rico
  2. Dec 11, 2012Phase 3 study in AnemiaNCT01750190 · 922 enrolled · United States, Argentina, Australia and more
  3. Jan 6, 2014Phase 3 study in AnemiaNCT02052310 · 1,043 enrolled · United States, Argentina, Bulgaria and more
  4. Oct 22, 2014Phase 3 study in AnemiaNCT02273726 · 741 enrolled · United States, Puerto Rico
  5. Dec 31, 20152 phase 3 studies in AnemiaNCT02652819, NCT02652806
  6. Aug 22, 2017Phase 3 study in AnemiaNCT03263091 · 184 enrolled · United States, Australia, Belgium and more
  7. Oct 2, 2017Phase 3 study in AnemiaNCT03303066 · 43 enrolled · China
  8. Aug 8, 2019Phase 4 study in AnemiaNCT04059913 · 318 enrolled · China
  9. Aug 30, 2019Phase 2 study in AnemiaNCT04076943 · 92 enrolled · United States
  10. May 27, 2020Phase 3 study in Anemia Associated With End Stage Renal Disease (ESRD)NCT04410198 · 203 enrolled · United States
  11. Jul 21, 2020Phase 3 study in Anemia Associated With End Stage Renal DiseaseNCT04484857 · 283 enrolled · United States
  12. Nov 3, 2020Phase 3 study in AnemiaNCT04621331 · United States
  13. Mar 19, 2022Phase 3 study in Chemotherapy Induced AnemiaNCT05301517 · 159 enrolled · China
  14. Jul 20, 2026Phase 3 study in Myelodysplastic SyndromesNCT07722988 · 201 planned

Ahead

  1. Sep 2030Primary completion: phase 3 study in Myelodysplastic SyndromesNCT07722988

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 22 Kyntra Bio leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722988Myelodysplastic Syndromes3Not yet recruitingSep 2030201
NCT05301517Chemotherapy Induced Anemia · China3CompletedApr 3, 2023159
NCT04621331Anemia · United States3WithdrawnMay 23, 20220
NCT04484857Anemia Associated With End Stage Renal Disease · United States3CompletedJul 9, 2021283
NCT04410198Anemia Associated With End Stage Renal Disease (ESRD) · United States3CompletedJun 30, 2021203
NCT04076943Anemia · United States2CompletedMar 26, 202192
NCT04059913Anemia · China4CompletedNov 19, 2021318
NCT03303066Anemia · China3CompletedJan 11, 202343
NCT03263091Anemia · United States, Australia, Belgium and more3TerminatedMar 9, 2023184
NCT02652819Anemia · China3CompletedJan 24, 2017154
NCT02652806Anemia · China3CompletedJan 24, 2017305
NCT02273726Anemia · United States, Puerto Rico3CompletedSep 19, 2018741
NCT02052310Anemia · United States, Argentina, Bulgaria and more3CompletedSep 21, 20181,043
NCT01750190Anemia · United States, Argentina, Australia and more3CompletedSep 24, 2018922
NCT01630889Renal Insufficiency, Chronic · United States, Puerto Rico2CompletedDec 12, 201915
NCT01599507Anemia · China2CompletedJan 201391
NCT01596855Anemia · China2CompletedJan 201396
NCT01414075Anemia · United States, Hong Kong, Russian Federation and more2CompletedJan 10, 201360
NCT01376063Healthy Adult Subjects1CompletedMay 201020
NCT01244763Renal Insufficiency, Chronic · United States, Puerto Rico2CompletedJun 13, 2012145
NCT01147666Kidney Failure, Chronic · United States2CompletedOct 15, 2012161
NCT00761657Renal Insufficiency, Chronic · United States2CompletedJun 21, 2010117

How it is read

Names in the registry

  • “Roxadustat”, 25 entries
  • “FG-4592”, 9 entries
  • “roxadustat”, 8 entries
  • “ASP1517”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.